- Home
- ATNF vs LIXT Comparison
ATNF vs LIXT Comparison
Compare ATNF & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- LIXT
- Stock Information
- Founded
- ATNF 2016
- LIXT 2005
- Country
- ATNF United States
- LIXT United States
- Employees
- ATNF N/A
- LIXT N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- LIXT Health Care
- Exchange
- ATNF Nasdaq
- LIXT Nasdaq
- Market Cap
- ATNF 4.1M
- LIXT 4.1M
- IPO Year
- ATNF N/A
- LIXT N/A
- Fundamental
- Price
- ATNF $0.85
- LIXT $1.18
- Analyst Decision
- ATNF
- LIXT
- Analyst Count
- ATNF 0
- LIXT 0
- Target Price
- ATNF N/A
- LIXT N/A
- AVG Volume (30 Days)
- ATNF 32.3K
- LIXT 31.5K
- Earning Date
- ATNF 05-14-2025
- LIXT 03-24-2025
- Dividend Yield
- ATNF N/A
- LIXT N/A
- EPS Growth
- ATNF N/A
- LIXT N/A
- EPS
- ATNF N/A
- LIXT N/A
- Revenue
- ATNF N/A
- LIXT N/A
- Revenue This Year
- ATNF N/A
- LIXT N/A
- Revenue Next Year
- ATNF N/A
- LIXT N/A
- P/E Ratio
- ATNF N/A
- LIXT N/A
- Revenue Growth
- ATNF N/A
- LIXT N/A
- 52 Week Low
- ATNF $0.85
- LIXT $1.02
- 52 Week High
- ATNF $17.75
- LIXT $3.74
- Technical
- Relative Strength Index (RSI)
- ATNF 28.88
- LIXT 38.93
- Support Level
- ATNF $0.83
- LIXT $1.15
- Resistance Level
- ATNF $1.02
- LIXT $1.29
- Average True Range (ATR)
- ATNF 0.08
- LIXT 0.09
- MACD
- ATNF -0.01
- LIXT 0.02
- Stochastic Oscillator
- ATNF 7.76
- LIXT 10.71
Stock Price Comparison Chart: ATNF vs LIXT
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp is a clinical-stage biotechnology company. It is focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis by employing innovative research, and, where appropriate, combination therapy.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.